HT
BBIO icon

HAP Trading’s BridgeBio Pharma BBIO Stock Holding History

HAP Trading’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$90K – 686
2024
Q1 		$90K Buy
+50,000
New +$1.7M 0.01% 367
2023
Q3 		– Sell
-336,700
Closed -$384K – 1047
2023
Q2 		$384K Buy
+336,700
New +$5.07M 0.07% 216
2022
Q3 		– Sell
-20,700
Closed -$64K – 1737
2022
Q2 		$64K Buy
20,700
+300
+1% +$2.51K ﹤0.01% 990
2022
Q1 		$53K Sell
20,400
-440,000
-96% -$4.52M ﹤0.01% 1235
2021
Q4 		$2.96M Buy
460,400
+298,000
+183% +$12.6M 0.08% 220
2021
Q3 		$1.63M Buy
162,400
+12,200
+8% +$654K 0.05% 324
2021
Q2 		$1.18M Buy
150,200
+100
+0.1% +$5.71K 0.04% 409
2021
Q1 		$1.49M Buy
+150,100
New +$9.82M 0.08% 239

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's BBIO Position: Q2 2024 in Review

HAP Trading sold out of BridgeBio Pharma (BBIO) in Q2 2024, closing a stake of 38,039 shares — an estimated $1.04M sold.

HAP Trading first reported a position in BBIO in Q1 2021 and held it in 6 quarters. The position peaked at $7.56M in Q4 2021. 251 funds tracked by Wall St. Rank hold BBIO as of Q2 2024.

  • HAP Trading reported no remaining BridgeBio Pharma position as of Q2 2024 after selling out during the quarter.
  • HAP Trading sold 38,039 BridgeBio Pharma shares in Q2 2024, an estimated $1.04M.
  • HAP Trading first reported a position in BridgeBio Pharma in Q1 2021 and held it in 6 quarters.
  • HAP Trading's BridgeBio Pharma position peaked at $7.56M in Q4 2021.
  • 251 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2024.

Based on HAP Trading's 13F filing for Q2 2024, filed 14 Aug 2024.